MedWatch

IO Biotech CEO after US failure: "It doesn't worry me"

A number of US pharmaceutical companies have stopped their trials with the enzyme IDO after a US company failed in phase 3, but it does not scare Danish IO Biotech that works with the same enzyme as the company has a different approach than the US companies.

Mai-Britt Zocca, CEO of IO Biotech. | Foto: IO Biotech.

The Copenhagen-based biotech company IO Biotech will not be deterred by the fact that a number of US giants have dropped clinical studies with the enzyme IDO, which IO Biotech's main asset deals with.

Both Merck/MSD, Bristol-Meyers Squibb, AstraZeneca and Roche have dropped IDO programs after the US biotech company Incyte failed a phase 3 study in April.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier